SCHEMBL2902803

SCHEMBL2902803

CCN(CC)Cc1cn(-c2ccc(-c3ccc(OC)cc3)cc2)nc1-c1ccco1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.48
MAPT P10636 6/20 0.48
ALDH1A1 P00352 5/20 0.48
NPC1 O15118 4/20 0.48
RAB9A P51151 4/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
HTT P42858 2/20 0.47
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
POLB P06746 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
NLRP3 Q96P20 1/20 0.42
TSHR P16473 2/20 0.41
HSD17B10 Q99714 2/20 0.41
HPGD P15428 1/20 0.41
PTGS1 P23219 1/20 0.41
PTGS2 P35354 1/20 0.41
CCNE1 P24864 4/20 0.41
CDK2 P24941 4/20 0.41
MAPK1 P28482 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2901798 0.87 MAPT (0.50) KDM4EMAPTALDH1A1NPC1SMN1; SMN2
SCHEMBL2902669 0.83 ALDH1A1 (0.46) KDM4EMAPTALDH1A1NPC1RAB9A
SCHEMBL2908535 0.82 ALDH1A1 (0.43) KDM4EMAPTALDH1A1NPC1RAB9A
SCHEMBL2904628 0.79 KDM4E (0.51) KDM4EMAPTALDH1A1NPC1RAB9A
SCHEMBL2908994 0.79 ALDH1A1 (0.52) KDM4EMAPTALDH1A1NPC1RAB9A
SCHEMBL2905922 0.78 ALDH1A1 (0.52) KDM4EMAPTALDH1A1NPC1RAB9A
SCHEMBL5224717 0.77 NPBWR1 (0.45) KDM4EMAPTALDH1A1NPC1RAB9A
SCHEMBL2901673 0.75 ALDH1A1 (0.51) KDM4EMAPTALDH1A1NPC1RAB9A
SCHEMBL2902226 0.75 SSTR5 (0.49) KDM4EMAPTALDH1A1NPC1RAB9A
SCHEMBL2908986 0.72 ALDH1A1 (0.45) KDM4EMAPTALDH1A1NPC1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP claimed
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP disclosed
US-7566709-B2 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2009-07-28 US disclosed
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders HTR1A, HTR1D, HTR5A KDM4E 3489/4885MAPT 1204/4885ALDH1A1 1336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.